Becton Dickinson and Company: 10-K Risk Factor Changes

2025 vs 2024  ·  SEC EDGAR  ·  2026-07-05
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

4
New Risks
1
Removed
19
Modified
7
Unchanged
🟢 New in Current Filing Severity10/10Det 10

The development, deployment and use of AI in our products and business operations generally could result in regulatory action, legal liability, operational challenges or reputational harm and our failure to adapt to medical technology industry trends and developments related to AI in a timely manner (or at all) could adversely affect our business, financial condition, results of operations and cash flows.

We have integrated (and expect to continue to integrate) AI into our products and business operations generally. We also expect to continue to develop future uses of AI and expand our existing AI capabilities to include agentic solutions, as well as pursue new AI technology…

Read full text

We have integrated (and expect to continue to integrate) AI into our products and business operations generally. We also expect to continue to develop future uses of AI and expand our existing AI capabilities to include agentic solutions, as well as pursue new AI technology partnerships with third parties. The development, deployment and use of AI (particularly generative AI) is in the early stages and presents various 19 19 19 19 19 19 Table of Contents Table of Contents Table of Contents risks, including from confidentiality, privacy, data protection, cybersecurity and compliance perspectives, and raises intellectual property issues and legal, regulatory, reputational ethical, operational, technological and other concerns (see, “Our operations are dependent in part on patents and other intellectual property assets” and “Cybersecurity incidents and breaches or breakdowns of our information and technology systems or infrastructure could have a material adverse effect on our operations” elsewhere in this Item 1A, Risk Factors). Additionally, if we do not effectively adopt and integrate AI into innovative, market-differentiated products in a timely manner, our competitive position could be adversely affected.

🟢 New in Current Filing The proposed combination of our Biosciences and Diagnostic Solutions business with Waters may not be completed, on the currently contemplated timeline or at all. 🔒
🟢 New in Current Filing The announcement and pendency of the combination of our Biosciences and Diagnostic Solutions business with Waters could cause disruptions in our business. 🔒
🟢 New in Current Filing We may not realize some or all of the expected benefits of the combination of our Biosciences and Diagnostic Solutions business with Waters. 🔒
🟡 Modified Cybersecurity incidents and breaches or breakdowns of our information and technology systems or infrastructure could have a material adverse effect on our operations. 🔒
🟡 Modified We are subject to extensive regulation. 🔒
🟡 Modified Our international operations subject us to certain business risks. 🔒
🟡 Modified Market dynamics, changes in reimbursement practices and coverage policies, third-party payer cost containment measures and health insurance coverage levels could affect demand for our products and the prices at which they are sold. 🔒
🔴 No Match in Current Filing We are subject to risks associated with public health crises, such as pandemics and epidemics, which could have a material adverse effect on our business. The nature and extent of impacts from any such events are highly uncertain and unpredictable. 🔒
🟡 Modified Climate change and related sustainability efforts, or legal, regulatory or market measures to address these efforts, could adversely affect our business, financial condition or results of operations. 🔒
🟡 Modified The medical technology industry is very competitive. 🔒
🟡 Modified Global economic conditions, including inflation and supply chain disruptions, could continue to adversely affect our operations. 🔒
🟡 Modified Cost volatility could adversely affect our operations. 🔒
🟡 Modified Interruption of our manufacturing or sterilization operations could adversely affect our business. 🔒
🟡 Modified We are subject to foreign currency exchange risk. 🔒
🟡 Modified Natural disasters, public health crises, war and other events beyond our control could disrupt our business and adversely affect our future revenues and operating income. 🔒
🟡 Modified Human Capital Management 🔒
🟡 Modified Information About our Executive Officers 🔒
🟡 Modified We are subject to lawsuits. 🔒
🟡 Modified Defects or quality issues associated with our products and related regulatory actions could adversely affect our results of operations and financial statements. 🔒
🟡 Modified Reductions in customers’ research budgets or government funding may adversely affect our business. 🔒
🟡 Modified Forward-Looking Statements 🔒
🟡 Modified The agreements that govern our indebtedness impose restrictions that may affect our ability to operate our businesses. 🔒
🟡 Modified Risks Relating to the Spin-off of Embecta Corp. 🔒
23 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →